Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have been given a consensus rating of “Buy” by the ten analysts that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $52.14.
Several analysts have commented on DNTH shares. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim restated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th.
Check Out Our Latest Analysis on DNTH
Dianthus Therapeutics Trading Up 0.2 %
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Dianthus Therapeutics
Large investors have recently made changes to their positions in the business. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $26,000. Quest Partners LLC increased its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $59,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- How to Build the Ultimate Everything ETF Portfolio
- Consumer Discretionary Stocks Explained
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the S&P/TSX Index?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.